|Slideshows|February 28, 2019

Neuropsychiatric Symptoms in Huntington Disease: A 5-Question Quiz

Are you up-to-date on recent guidelines for the management of agitation, anxiety, apathy, psychosis, and sleep disorders in patients with Huntington disease? Take this brief quiz to find out.

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related to this article

October 14th, 2026

Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression

A post hoc analysis of the phase 2/3 NPC002 trial presented at CNS 2026 showed that the benefit of arimoclomol plus miglustat in Niemann-Pick disease type C emerged as early as 3 months after treatment initiation.

October 23rd, 2026

Remibrutinib Lowers Relapse Rate vs Teriflunomide in Relapsing MS

Phase 3 data show the oral BTK inhibitor reduced annualized relapse rate by 35.2% and 31.2% vs teriflunomide, with no liver safety signal or Hy's Law cases.

October 23rd, 2026

NeurologyLive® Friday 5 — October 23, 2026

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.

October 23rd, 2026

Endovascular Therapy Benefit in Distal Vessel Stroke Tied to Severity, Not IVT Status

A secondary analysis of the DISTAL trial found endovascular therapy's benefit depended more on stroke severity than on prior thrombolysis treatment.

October 22nd, 2026

FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.

October 22nd, 2026

More Time in Target Blood Pressure Range Cuts Recurrent Stroke After Intracerebral Hemorrhage

A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.

October 22nd, 2026

Liposomal Mitoxantrone Shows Early Safety Signal in Phase 2 NMOSD Trial

A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.

October 22nd, 2026

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Neuropsychiatric Symptoms in Huntington Disease: A 5-Question Quiz

Related to this article

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated

Advances in Spinal Cord MRI for Multiple Sclerosis: Julien Cohen-Adad, PhD

Remibrutinib Lowers Relapse Rate vs Teriflunomide in Relapsing MS

Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis